If there's one thing that Novartis ($NVS) CEO Joe Jimenez likes to talk about, it's efficiency.
The idea of facing generic competition for a $5 billion blockbuster like Diovan would daunt almost any CEO. But Joe Jimenez (photo) says his experience hawking baby food and ketchup at Heinz made him
Maybe it's the rarefied Davos air or the long-range mountain views, but Novartis ($NVS) CEO Joe Jimenez is feeling optimistic about the post- Diovan future. After the Swiss drugmaker loses patent...
Don't accuse Novartis ($NVS) CEO Joe Jimenez (photo) of refusing to listen. After workers in Nyon, Switzerland, stopped work to protest their plant's closure, the company sat down to talk about other
Novartis ($NVS) CEO Joe Jimenez (photo) is no stranger to the executive Q&A; he's been chatted up by almost every big media outlet there is. However, every once in a while, he drops a bit of new
The good news for Novartis ($NVS): Workers in Nyon, Switzerland, have ended their strike. The not-so-good: If union leaders and employees think the drugmaker isn't negotiating in good faith, they'll
Swiss workers haven't taken Novartis' ($NVS) job-cutting plans lying down. First, union members and political activists joined protests in Basel--including one at Chairman Daniel Vasella's (photo)
Novartis ($NVS) has put a number to its job-cutting plans. The Swiss-based drugmaker will shed 2,000 jobs in its home country and the U.S., while shutting down expensive-to-operate European
With Joe Jimenez at the helm, Novartis ($NVS) has consistently vowed to back its multibillion-dollar R&D empire, avoiding the wholesale restructuring that has upended research operations at many
Novartis ($NVS) CEO Joe Jimenez (photo) tells the New York Times a few things: He's more patient than he used to be. He's learned how to open the door to bad news. And he's not one to compliment a